Clinical immunologic approaches for the treatment of Alzheimer's disease

Beka Solomon*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


Recent clinical trials of active vaccination against β-amyloid (Aβ) have succeeded in clearing Aβ plaques; however, further understanding of immunization with regards to inflammation and other hallmarks of Alzheimer's disease pathology is required. Antibodies generated with this first-generation vaccine may not have had the desired therapeutic properties or targeted the 'correct' mechanism, but they have opened the way for new clinical approaches, which are now under consideration. Passive administration of monoclonal antibodies directed to various regions of Aβ peptide and/or administration of immunoconjugates of only small fragments of the N-terminal region may lead to the development of an improved second generation of Aβ vaccines. Amyloid immunotherapy offers genuine opportunities for disease treatment; however, such an approach towards treating and preventing Alzheimer's disease patients requires careful antigen and antibody selection to maximize efficacy and minimize adverse events.

Original languageEnglish
Pages (from-to)819-828
Number of pages10
JournalExpert Opinion on Investigational Drugs
Issue number6
StatePublished - Jun 2007


  • Active immunization
  • Alzheimer's disease
  • Cognitive functions
  • Immunotherapy
  • Passive immunization
  • Site-directed antibodies
  • β-amyloid


Dive into the research topics of 'Clinical immunologic approaches for the treatment of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this